Dynavax Technologies Corp. (DVAX) on Thursday said that its experimental Shingles vaccine yielded positive results in an ...

Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's blockbuster shot Shingrix, while showing a better safety profile, in ...

Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.

Shares of Dynavax rose after the company released positive results from a trial of its shingles vaccine tested against current Shingles vaccine Shingrix. The stock was up 6.7% to $11.12 but is still ...

Dynavax (DVAX) stock gains as the company's Z-1018 shingles shot shows immune response comparable to GSK's (GSK) Shingrix vaccine in a Phase 1/2 trial. Read more here.

Investing.com -- Dynavax Technologies Corporation (NASDAQ: DVAX) stock soared 8% Thursday after the company announced positive topline results from its Phase 1/2 clinical trial for Z-1018, its ...

Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

On August 21, 2025, Dynavax announced positive topline results from Part 1 of its Phase 1/2 clinical trial for Z-1018, a novel shingles vaccine candidate. The trial showed that Z-1018 has comparable ...

Dynavax Technologies Corporation (NASDAQ: DVAX) Q2 2025 Earnings Call Transcript August 7, 2025 Dynavax Technologies ...

Dynavax delivers record Q2 results with $92M in HEPLISAV-B revenue, updates 2025 guidance, and advances pipeline milestones.

Key Points Dynavax Technologies (NASDAQ:DVAX) exceeded analyst expectations in Q2 2025, reporting GAAP revenue of $95.4 million and GAAP diluted EPS of $0.14. HEPLISAV-B, Dynavax's two-dose adult ...

EMERYVILLE, Calif. (AP) — EMERYVILLE, Calif. (AP) — Dynavax Technologies Corp. (DVAX) on Thursday reported earnings of $18.7 million in its second quarter.